Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 9/18/2025

Role of Tigecycline in Pneumonia Treatment

Introduction to Tigecycline Use

  • Tigecycline should not be used as monotherapy for the treatment of pneumonia, particularly hospital-acquired or ventilator-associated pneumonia, due to higher mortality rates and treatment failure compared to alternative therapies 1, 2

Evidence Against Monotherapy

  • Tigecycline monotherapy has demonstrated a higher rate of treatment failure compared to colistin monotherapy, colistin combination therapy, and sulbactam-based therapy for carbapenem-resistant Acinetobacter baumannii (CRAB) pneumonia 1, 3
  • A matched cohort study comparing colistin versus tigecycline favored colistin-based therapy for multi-drug-resistant (MDR) pneumonia 1
  • The excess mortality with tigecycline may be related to higher A. baumannii MIC of tigecycline (>2 mg/mL) 1
  • Guidelines strongly recommend against tigecycline monotherapy for the treatment of CRAB pneumonia 4

Combination Therapy Considerations

  • For carbapenem-resistant Acinetobacter baumannii (CRAB) pneumonia, tigecycline may be considered as part of combination therapy when the MIC is ≤2 mg/L 5
  • A randomized study of extensively drug-resistant A. baumannii ventilator-associated pneumonia showed that combination of tigecycline and cefoperazone-sulbactam had synergistic activity and higher clinical response rates than tigecycline monotherapy 1
  • For CRAB pneumonia, guidelines suggest colistin with or without carbapenems as the preferred treatment, with tigecycline only as part of combination therapy in specific scenarios 4, 5

Alternative Treatments

  • For CRAB pneumonia, colistin (with or without carbapenems) and adjunctive inhaled colistin therapy is recommended as first-line treatment 4, 5
  • Alternative treatments for CRAB pneumonia include high-dose sulbactam (6-9 g/day) or triple therapy with colistin, tigecycline, and sulbactam 5
  • For Pseudomonas aeruginosa infections, tigecycline is not recommended due to inadequate activity 7

Pharmacokinetic and Adverse Effect Considerations

  • Despite good tissue penetration, tigecycline performs poorly in bacteremic patients due to low plasma concentrations 6
  • The clinical efficacy of tigecycline is associated with its MIC value against MDR organisms - comparable to polymyxin when MIC ≤2 mg/L, but inferior when MIC >2 mg/L 6
  • Common adverse effects include nausea, vomiting, and diarrhea 6
  • Patients should be monitored for adverse effects, particularly gastrointestinal symptoms and liver function abnormalities 6

REFERENCES

2

recommendations and guidelines for the treatment of pneumonia in taiwan. [LINK]

Journal of Microbiology, Immunology and Infection, 2019

6

Treatment of Pseudomonas aeruginosa Infections [LINK]

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

7

Role of Tigecycline in Treating Bone Infections [LINK]

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025